Great_老虎社区_美港股上老虎

TiggyTrader
2021-07-02

Great

J&J's COVID-19 vaccine shows strong activity against Delta variant

July 1 (Reuters) - Johnson & Johnson said late Thursday that its single-shot COVID-19 vaccine genera

J&J's COVID-19 vaccine shows strong activity against Delta variant

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":156390522,"tweetId":"156390522","gmtCreate":1625193721766,"gmtModify":1633942674145,"author":{"id":3555369166820250,"idStr":"3555369166820250","authorId":3555369166820250,"authorIdStr":"3555369166820250","name":"TiggyTrader","avatar":"https://static.tigerbbs.com/bf3a767c22416849fe76f2e38a327e6c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Great&nbsp;</p></body></html>","text":"Great","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/156390522","repostId":2148082034,"repostType":4,"repost":{"id":"2148082034","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625187209,"share":"https://www.laohu8.com/m/news/2148082034?lang=&edition=full","pubTime":"2021-07-02 08:53","market":"us","language":"en","title":"J&J's COVID-19 vaccine shows strong activity against Delta variant","url":"https://stock-news.laohu8.com/highlight/detail?id=2148082034","media":"Reuters","summary":"July 1 (Reuters) - Johnson & Johnson said late Thursday that its single-shot COVID-19 vaccine genera","content":"<p>July 1 (Reuters) - Johnson &amp; Johnson said late Thursday that its single-shot COVID-19 vaccine generated strong, persistent activity against the Delta and other highly prevalent variants.</p>\n<p>Data showed that the durability of the immune response lasted through at least eight months, the U.S.-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.</p>\n<p>\"Current data for the eight months studied so far shows that the single-shot Johnson &amp; Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,\" Mathai Mammen, head of research &amp; development at J&amp;J's drugs business, said in the statement.</p>\n<p>The COVID-19 vaccine elicited neutralizing antibody activity against the Delta variant, first identified in India, at an even higher level than what was observed for the Beta variant, which was first detected in South Africa, the company said.</p>\n<p>J&amp;J has submitted data as a preprint to the website bioRxiv ahead of peer review.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J's COVID-19 vaccine shows strong activity against Delta variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J's COVID-19 vaccine shows strong activity against Delta variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-02 08:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 1 (Reuters) - Johnson &amp; Johnson said late Thursday that its single-shot COVID-19 vaccine generated strong, persistent activity against the Delta and other highly prevalent variants.</p>\n<p>Data showed that the durability of the immune response lasted through at least eight months, the U.S.-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.</p>\n<p>\"Current data for the eight months studied so far shows that the single-shot Johnson &amp; Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,\" Mathai Mammen, head of research &amp; development at J&amp;J's drugs business, said in the statement.</p>\n<p>The COVID-19 vaccine elicited neutralizing antibody activity against the Delta variant, first identified in India, at an even higher level than what was observed for the Beta variant, which was first detected in South Africa, the company said.</p>\n<p>J&amp;J has submitted data as a preprint to the website bioRxiv ahead of peer review.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148082034","content_text":"July 1 (Reuters) - Johnson & Johnson said late Thursday that its single-shot COVID-19 vaccine generated strong, persistent activity against the Delta and other highly prevalent variants.\nData showed that the durability of the immune response lasted through at least eight months, the U.S.-based healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death.\n\"Current data for the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time,\" Mathai Mammen, head of research & development at J&J's drugs business, said in the statement.\nThe COVID-19 vaccine elicited neutralizing antibody activity against the Delta variant, first identified in India, at an even higher level than what was observed for the Beta variant, which was first detected in South Africa, the company said.\nJ&J has submitted data as a preprint to the website bioRxiv ahead of peer review.","news_type":1},"isVote":1,"tweetType":1,"viewCount":334,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}